<s id="wsj_1739.1"> 25
2 	 0 	 N/N 	 1 	 Co. Bristol-Myers
2 	 1 	 N/N 	 1 	 Co. Squibb
2 	 5 	 NP\NP 	 1 	 Co. York
2 	 15 	 (S[dcl]\NP)/NP 	 1 	 Co. reported
5 	 4 	 (NP\NP)/(NP\NP) 	 2 	 York New
9 	 8 	 (N/N)/(N/N) 	 2 	 merged newly
10 	 7 	 NP[nb]/N 	 1 	 drug the
10 	 9 	 N/N 	 1 	 drug merged
10 	 15 	 (S[dcl]\NP)/NP 	 1 	 drug reported
13 	 7 	 NP[nb]/N 	 1 	 company the
13 	 9 	 N/N 	 1 	 company merged
13 	 12 	 N/N 	 1 	 company health-care-product
13 	 15 	 (S[dcl]\NP)/NP 	 1 	 company reported
18 	 15 	 (S[dcl]\NP)/NP 	 2 	 earnings reported
18 	 16 	 N/N 	 1 	 earnings record
18 	 17 	 N/N 	 1 	 earnings third-quarter
18 	 19 	 (NP\NP)/NP 	 1 	 earnings for
21 	 19 	 (NP\NP)/NP 	 2 	 companies for
21 	 20 	 NP[nb]/N 	 1 	 companies both
21 	 22 	 (NP\NP)/NP 	 1 	 companies in
24 	 22 	 (NP\NP)/NP 	 2 	 merger in
24 	 23 	 NP[nb]/N 	 1 	 merger the
<\s>
<s id="wsj_1739.2"> 24
1 	 0 	 N/N 	 1 	 Co. Bristol-Myers
1 	 10 	 S[dcl]\NP 	 1 	 Co. merged
4 	 3 	 N/N 	 1 	 Corp. Squibb
4 	 6 	 NP\NP 	 1 	 Corp. Princeton
4 	 8 	 NP\NP 	 1 	 Corp. N.J. <XU>
4 	 10 	 S[dcl]\NP 	 1 	 Corp. merged
10 	 11 	 ((S\NP)\(S\NP))/N[num] 	 2 	 merged Oct.
12 	 11 	 ((S\NP)\(S\NP))/N[num] 	 3 	 4 Oct.
17 	 15 	 NP[nb]/N 	 1 	 company the
17 	 16 	 N/N 	 1 	 company new
17 	 18 	 (S[dcl]\NP)/NP 	 1 	 company reported
20 	 18 	 (S[dcl]\NP)/NP 	 2 	 earnings reported
20 	 19 	 N/N 	 1 	 earnings third-period
20 	 21 	 (NP\NP)/NP 	 1 	 earnings for
23 	 21 	 (NP\NP)/NP 	 2 	 companies for
23 	 22 	 NP[nb]/N 	 1 	 companies both
<\s>
<s id="wsj_1739.3"> 13
3 	 0 	 (S/S)/NP 	 2 	 quarter For
3 	 1 	 NP[nb]/N 	 1 	 quarter the
3 	 2 	 N/N 	 1 	 quarter fourth
6 	 5 	 N/N 	 1 	 Squibb Bristol-Myers
6 	 7 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Squibb will
6 	 8 	 (S[b]\NP)/NP 	 1 	 Squibb report <XB>
7 	 0 	 (S/S)/NP 	 1 	 will For
8 	 7 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 report will
10 	 8 	 (S[b]\NP)/NP 	 2 	 set report
10 	 9 	 N/N 	 1 	 set one
10 	 11 	 (NP\NP)/NP 	 1 	 set of
12 	 11 	 (NP\NP)/NP 	 2 	 earnings of
<\s>
<s id="wsj_1739.4"> 32
0 	 1 	 (S[dcl]\NP)/S[dcl] 	 1 	 Bristol-Myers said
3 	 2 	 N/N 	 1 	 income net
3 	 4 	 S[dcl]\NP 	 1 	 income rose
4 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 rose said
4 	 6 	 (S\NP)\(S\NP) 	 2 	 rose %
4 	 7 	 ((S\NP)\(S\NP))/NP 	 2 	 rose to
4 	 18 	 ((S\NP)\(S\NP))/NP 	 2 	 rose from
6 	 5 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 15
8 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
10 	 8 	 N/N[num] 	 1 	 million $
10 	 9 	 N/N 	 1 	 million 266.2
14 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 cents to
14 	 13 	 N/N 	 1 	 cents 93
14 	 15 	 (NP\NP)/N 	 1 	 cents a
16 	 15 	 (NP\NP)/N 	 2 	 share a
18 	 31 	 (((S\NP)\(S\NP))\((S\NP)\(S\NP)))\NP 	 3 	 from earlier
19 	 18 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
21 	 19 	 N/N[num] 	 1 	 million $
21 	 20 	 N/N 	 1 	 million 232.3
25 	 18 	 ((S\NP)\(S\NP))/NP 	 3 	 cents from
25 	 24 	 N/N 	 1 	 cents 81
25 	 26 	 (NP\NP)/N 	 1 	 cents a
27 	 26 	 (NP\NP)/N 	 2 	 share a
30 	 29 	 NP[nb]/N 	 1 	 year a
30 	 31 	 (((S\NP)\(S\NP))\((S\NP)\(S\NP)))\NP 	 4 	 year earlier
<\s>
<s id="wsj_1739.5"> 12
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 Sales gained
1 	 4 	 ((S\NP)\(S\NP))/NP 	 2 	 gained to
1 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 gained from
3 	 1 	 (S[dcl]\NP)/NP 	 2 	 % gained
3 	 2 	 N/N 	 1 	 % 5
5 	 4 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
7 	 5 	 N/N[num] 	 1 	 billion $
7 	 6 	 N/N 	 1 	 billion 1.59
9 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
11 	 9 	 N/N[num] 	 1 	 billion $
11 	 10 	 N/N 	 1 	 billion 1.52
<\s>
<s id="wsj_1739.6"> 28
1 	 0 	 N/N 	 1 	 Corp. Squibb
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 Corp. said
3 	 4 	 S[dcl]\NP 	 1 	 net rose
4 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 rose said
4 	 6 	 (S\NP)\(S\NP) 	 2 	 rose %
4 	 7 	 ((S\NP)\(S\NP))/NP 	 2 	 rose to
4 	 18 	 ((S\NP)\(S\NP))/NP 	 2 	 rose from
6 	 5 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 17
8 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
10 	 8 	 N/N[num] 	 1 	 million $
10 	 9 	 N/N 	 1 	 million 144.5
13 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
13 	 15 	 (NP\NP)/N 	 1 	 $ a
14 	 13 	 N/N[num] 	 1 	 1.47 $
16 	 15 	 (NP\NP)/N 	 2 	 share a
19 	 18 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
21 	 19 	 N/N[num] 	 1 	 million $
21 	 20 	 N/N 	 1 	 million 123
24 	 18 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
24 	 26 	 (NP\NP)/N 	 1 	 $ a
25 	 24 	 N/N[num] 	 1 	 1.25 $
27 	 26 	 (NP\NP)/N 	 2 	 share a
<\s>
<s id="wsj_1739.7"> 13
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 Sales were
1 	 6 	 (((S\NP)\(S\NP))/PP)/NP 	 2 	 were up
2 	 1 	 (S[dcl]\NP)/NP 	 2 	 $ were
4 	 2 	 N/N[num] 	 1 	 million $
4 	 3 	 N/N 	 1 	 million 730.1
8 	 6 	 (((S\NP)\(S\NP))/PP)/NP 	 4 	 % up
8 	 7 	 N/N 	 1 	 % 7
9 	 6 	 (((S\NP)\(S\NP))/PP)/NP 	 3 	 from up
10 	 9 	 PP/NP 	 1 	 $ from
12 	 10 	 N/N[num] 	 1 	 million $
12 	 11 	 N/N 	 1 	 million 679.5
<\s>
<s id="wsj_1739.8"> 16
6 	 0 	 (S/S)/NP 	 2 	 trading In
6 	 1 	 N/N 	 1 	 trading New
6 	 2 	 N/N 	 1 	 trading York
6 	 3 	 N/N 	 1 	 trading Stock
6 	 4 	 N/N 	 1 	 trading Exchange
6 	 5 	 N/N 	 1 	 trading composite
9 	 8 	 N/N 	 1 	 Squibb Bristol-Myers
9 	 10 	 S[dcl]\NP 	 1 	 Squibb rose
10 	 0 	 (S/S)/NP 	 1 	 rose In
10 	 11 	 ((S\NP)\(S\NP))/N[num] 	 2 	 rose $
10 	 13 	 ((S\NP)\(S\NP))/NP 	 2 	 rose to
12 	 11 	 ((S\NP)\(S\NP))/N[num] 	 3 	 1.75 $
14 	 13 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
15 	 14 	 N/N[num] 	 1 	 52.75 $
<\s>
